Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 4 Interventional Results available

Assessment Of Dutasteride (AVODART) In Extending The Time To Progression Of Low-Risk, Localized Prostate Cancer In Men

ClinicalTrials.gov ID: NCT00363311

Public ClinicalTrials.gov record NCT00363311. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 8, 2026, 3:55 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Double-Blind, Placebo-Controlled Trial Assessing the Efficacy and Safety of Dutasteride in Extending the Time to Progression of Low-Risk, Localized Prostate Cancer in Men Who Are Candidates for or Undergoing Expectant Management

Study identification

NCT ID
NCT00363311
Recruitment status
Completed
Study type
Interventional
Phase
Phase 4
Lead sponsor
GlaxoSmithKline
Industry
Enrollment
302 participants

Conditions and interventions

Interventions

  • Dutasteride Drug
  • Matching placebo Drug

Drug

Eligibility (public fields only)

Age range
50 Years to 80 Years
Sex
Male
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jun 30, 2006
Primary completion
Feb 28, 2010
Completion
Jun 30, 2010
Last update posted
Jan 17, 2017

2006 – 2010

United States locations

U.S. sites
58
U.S. states
30
U.S. cities
57
Facility City State ZIP Site status
GSK Investigational Site Little Rock Arkansas 72211
GSK Investigational Site Beverly Hills California 90210
GSK Investigational Site Laguna Hills California 92653
GSK Investigational Site Mission Hills California 91345
GSK Investigational Site Modesto California 95350
GSK Investigational Site San Bernardino California 92404
GSK Investigational Site Torrance California 90506
GSK Investigational Site Englewood Colorado 80113
GSK Investigational Site Wheat Ridge Colorado 80033
GSK Investigational Site New Britain Connecticut 06052
GSK Investigational Site Trumbull Connecticut 06611
GSK Investigational Site Washington D.C. District of Columbia 20307
GSK Investigational Site Jacksonville Florida 32224
GSK Investigational Site Largo Florida 33773
GSK Investigational Site Orlando Florida 32803
GSK Investigational Site Roswell Georgia 30076
GSK Investigational Site Coeur d'Alene Idaho 83814
GSK Investigational Site Chicago Illinois 60612
GSK Investigational Site Melrose Park Illinois 60160
GSK Investigational Site Fort Wayne Indiana 46825
GSK Investigational Site Newburgh Indiana 47630
GSK Investigational Site Overland Park Kansas 66211
GSK Investigational Site Shreveport Louisiana 71106
GSK Investigational Site Annapolis Maryland 21401
GSK Investigational Site Greenbelt Maryland 20770
GSK Investigational Site Watertown Massachusetts 02472
GSK Investigational Site Minneapolis Minnesota
GSK Investigational Site Saint Cloud Minnesota 56303
GSK Investigational Site Jackson Mississippi 39202
GSK Investigational Site St Louis Missouri 63136
GSK Investigational Site Las Vegas Nevada 89148
GSK Investigational Site Marlton New Jersey 08053
GSK Investigational Site Albuquerque New Mexico 87109
GSK Investigational Site Albany New York 12208
GSK Investigational Site Elmont New York 11003
GSK Investigational Site Garden City New York 11530
GSK Investigational Site New York New York 10016
GSK Investigational Site Orchard Park New York 14127
GSK Investigational Site Syracuse New York 13210
GSK Investigational Site Greensboro North Carolina 27403
GSK Investigational Site Salisbury North Carolina 28144
GSK Investigational Site Winston-Salem North Carolina 27103
GSK Investigational Site Columbus Ohio 43214
GSK Investigational Site Springfield Oregon 97477
GSK Investigational Site Bala-Cynwyd Pennsylvania 19004
GSK Investigational Site Lancaster Pennsylvania 17604
GSK Investigational Site Philadelphia Pennsylvania 19107
GSK Investigational Site Memphis Tennessee 38119
GSK Investigational Site Nashville Tennessee 37232
GSK Investigational Site San Antonio Texas 78229
GSK Investigational Site Temple Texas 76508
GSK Investigational Site Salt Lake City Utah 84107
GSK Investigational Site Richmond Virginia 23235
GSK Investigational Site Virginia Beach Virginia 23455
GSK Investigational Site Williamsburg Virginia 23185
GSK Investigational Site Seattle Washington 98101
GSK Investigational Site Seattle Washington 98166
GSK Investigational Site Spokane Washington 99202

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 24 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00363311, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jan 17, 2017 · Synced May 8, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00363311 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →